已收录 268921 条政策
 政策提纲
  • 暂无提纲
The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems
[摘要] Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9), as a versatile genome engineering tool, has become popular in the biology research field and it was also applied to optimize tumor immunotherapy. Moreover, CRISPR-based high-throughput screening can be used in the study of immunomodulatory drug resistance mechanism. In this review, we summarized the development as well as the application of CRISPR/Cas9 technology in the cancer immunotherapy and discussed the potential problems that may be caused by this combination.
[发布日期] 2022-01-17 [发布机构] 
[效力级别]  [学科分类] 
[关键词] cancer;CRISPR/Cas9;immunotherapy;oncolytic viruses;immune checkpoints inhibition;CAR-T therapy [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文